Aura Biosciences, Inc. (AURA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$7.56+2.58%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AURA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete enrollment in the Phase 3 CoMpass trial for early choroidal melanoma by mid-2026 to support potential registration and topline data in 2H 2027.
Stated as a priority in 3 of last 3 quarters. The Phase 3 CoMpass trial enrollment completed with 108 patients by 2026-Q2, exceeding the target. Management has consistently reiterated the mid-2026 enrollment completion milestone and is delivering on this priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Phase 3 CoMpass trial fully enrolled with 108 patients, exceeding enrollment target.”
“Phase 3 CoMpass trial advancing toward enrollment completion, expected by mid-2026.”
“Expect to complete CoMpass enrollment by mid-2026.”
Provide topline data from the Phase 3 CoMpass trial's 15-month primary endpoint in the second half of 2027 as planned.
Stated as a priority in 3 of last 3 quarters. Management consistently expects topline data from the CoMpass trial in the second half of 2027, aligned with the trial's 15-month primary endpoint. The trajectory remains on track as per management's guidance.
“Topline data from the 15-month primary endpoint remain on track for 2H 2027.”
“Topline data for the 15-month primary endpoint anticipated in 2H 2027.”
“Provide topline data readout for the 15-month primary endpoint in Q4 2027.”
Refine strategic operating plan to prioritize ocular oncology development, including bel-sar, and minimize resource allocation to the NMIBC program.
Newly stated in 2026-Q2. Management announced a strategic refocus on ocular oncology, deprioritizing the NMIBC program to allocate resources more effectively. This is a recent shift with no prior quarters stating this priority.
“Strategic operating plan refined to focus on ocular oncology; NMIBC program being deprioritized.”
Maintain disciplined capital allocation and organizational restructuring to extend cash runway to support operations into the first half of 2029.
Stated in 2 of last 3 quarters. Cash and equivalents plus marketable securities increased to $323.8 million by 2026-Q2 from lower levels in prior periods. Management expects this, combined with restructuring, to extend the cash runway into 1H 2029, showing progress in capital allocation discipline.
“Actions expected to extend cash runway into the first half of 2029.”
“Cash and cash equivalents sufficient to fund operations into first half of 2027.”
Implement organizational realignment including a 20% workforce reduction to streamline operations and focus on ocular oncology.
Newly stated in 2026-Q2. Management announced a 20% workforce reduction as part of a strategic realignment to focus on ocular oncology. This restructuring is expected to be substantially complete by end of 2026-Q3.
“Organizational realignment to focus resources in ocular oncology with 20% workforce reduction.”
Over the trailing year it converted 0.92x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
19 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.